Sfoglia per Autore
Mostrati risultati da 1 a 14 di 14
Modified-Chronic Disease Score (M-CDS): Predicting the individual risk of death using drug prescriptions
2020-01-01 Iommi M.; Rosa S.; Fusaroli M.; Rucci P.; Fantini M.P.; Poluzzi E.
Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance
2020-01-01 Raschi E.; Fusaroli M.; Diemberger I.; Poluzzi E.
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment
2021-01-01 Raschi E.; Fusaroli M.; Ardizzoni A.; Poluzzi E.; De Ponti F.
Authors’ Reply to Robert P. Giugliano and Colleagues’ Comment on: “Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance”
2021-01-01 Raschi, Emanuel; Fusaroli, Michele; Diemberger, Igor; Poluzzi, Elisabetta
Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
2021-01-01 Raschi, Emanuel; Fusaroli, Michele; Ardizzoni, Andrea; Poluzzi, Elisabetta; De Ponti, Fabrizio
Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system
2021-01-01 Gatti M.; Fusaroli M.; Raschi E.; Moretti U.; Poluzzi E.; De Ponti F.
Impulsive conditions in Parkinson's disease: A pharmacosurveillance-supported list
2021-01-01 Fusaroli M.; Raschi E.; Contin M.; Sambati L.; Menchetti M.; Fioritti A.; Poluzzi E.
Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System
2021-01-01 Fusaroli M.; Raschi E.; Gatti M.; De Ponti F.; Poluzzi E.
Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis
2021-01-01 Filippini D.M.; Gatti M.; Di Martino V.; Cavalieri S.; Fusaroli M.; Ardizzoni A.; Raschi E.; Licitra L.
Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19
2021-01-01 Gatti M.; Fusaroli M.; Caraceni P.; Poluzzi E.; De Ponti F.; Raschi E.
Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry
2021-01-01 Aiello V.; Fusaroli M.; Raschi E.; Palazzini M.; Hu L.; Barbuto S.; Poluzzi E.; Capelli I.
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
2022-01-01 Sisi, Monia; Fusaroli, Michele; De Giglio, Andrea; Facchinetti, Francesco; Ardizzoni, Andrea; Raschi, Emanuel; Gelsomino, Francesco
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems
2022-01-01 Gatti M.; Fusaroli M.; Raschi E.; Capelli I.; Poluzzi E.; De Ponti F.
Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System
2022-01-01 Raschi E.; Fusaroli M.; La Placa M.; Ardizzoni A.; Zamagni C.; Poluzzi E.; De Ponti F.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Modified-Chronic Disease Score (M-CDS): Predicting the individual risk of death using drug prescriptions | Iommi M.; Rosa S.; Fusaroli M.; Rucci P.; Fantini M.P.; Poluzzi E. | 2020-01-01 | PLOS ONE | - | 1.01 Articolo in rivista | - |
| Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance | Raschi E.; Fusaroli M.; Diemberger I.; Poluzzi E. | 2020-01-01 | DRUG SAFETY | - | 1.01 Articolo in rivista | - |
| Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment | Raschi E.; Fusaroli M.; Ardizzoni A.; Poluzzi E.; De Ponti F. | 2021-01-01 | BREAST CANCER RESEARCH AND TREATMENT | - | 1.01 Articolo in rivista | - |
| Authors’ Reply to Robert P. Giugliano and Colleagues’ Comment on: “Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance” | Raschi, Emanuel; Fusaroli, Michele; Diemberger, Igor; Poluzzi, Elisabetta | 2021-01-01 | DRUG SAFETY | - | 1.04 Replica / breve intervento (e simili) | - |
| Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System | Raschi, Emanuel; Fusaroli, Michele; Ardizzoni, Andrea; Poluzzi, Elisabetta; De Ponti, Fabrizio | 2021-01-01 | CANCERS | - | 1.01 Articolo in rivista | - |
| Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system | Gatti M.; Fusaroli M.; Raschi E.; Moretti U.; Poluzzi E.; De Ponti F. | 2021-01-01 | EXPERT OPINION ON DRUG SAFETY | - | 1.01 Articolo in rivista | - |
| Impulsive conditions in Parkinson's disease: A pharmacosurveillance-supported list | Fusaroli M.; Raschi E.; Contin M.; Sambati L.; Menchetti M.; Fioritti A.; Poluzzi E. | 2021-01-01 | PARKINSONISM & RELATED DISORDERS | - | 1.01 Articolo in rivista | - |
| Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System | Fusaroli M.; Raschi E.; Gatti M.; De Ponti F.; Poluzzi E. | 2021-01-01 | FRONTIERS IN PHARMACOLOGY | - | 1.01 Articolo in rivista | - |
| Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis | Filippini D.M.; Gatti M.; Di Martino V.; Cavalieri S.; Fusaroli M.; Ardizzoni A.; Raschi E.; Licitra L. | 2021-01-01 | INTERNATIONAL JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
| Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19 | Gatti M.; Fusaroli M.; Caraceni P.; Poluzzi E.; De Ponti F.; Raschi E. | 2021-01-01 | BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | - | 1.01 Articolo in rivista | - |
| Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry | Aiello V.; Fusaroli M.; Raschi E.; Palazzini M.; Hu L.; Barbuto S.; Poluzzi E.; Capelli I. | 2021-01-01 | KIDNEY INTERNATIONAL REPORTS | - | 1.01 Articolo in rivista | - |
| Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System | Sisi, Monia; Fusaroli, Michele; De Giglio, Andrea; Facchinetti, Francesco; Ardizzoni, Andrea; Raschi, Emanuel; Gelsomino, Francesco | 2022-01-01 | TARGETED ONCOLOGY | - | 1.01 Articolo in rivista | Sisi2022_Article_PsychiatricAdverseReactionsToA.pdf; 11523_2021_865_MOESM1_ESM.pdf |
| Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems | Gatti M.; Fusaroli M.; Raschi E.; Capelli I.; Poluzzi E.; De Ponti F. | 2022-01-01 | JN. JOURNAL OF NEPHROLOGY | - | 1.01 Articolo in rivista | 40620_2021_1191_MOESM2_ESM.pptx; 40620_2021_1191_MOESM1_ESM.pptx |
| Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System | Raschi E.; Fusaroli M.; La Placa M.; Ardizzoni A.; Zamagni C.; Poluzzi E.; De Ponti F. | 2022-01-01 | AMERICAN JOURNAL OF CLINICAL DERMATOLOGY | - | 1.01 Articolo in rivista | - |
Mostrati risultati da 1 a 14 di 14
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile